Innovation | Novartis United States of America

Media Release
Jul 24, 2015
FDA approves Novartis drug Odomzo® (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer
Media Release
Jul 07, 2015
Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril/valsartan)
Media Release
Jun 11, 2015
Novartis presents new data at WCD that shows significant efficacy of Cosentyx® in patients with psoriasis of the palms, soles of feet and nails
Media Release
Jun 01, 2015
Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma
Media Release
May 31, 2015
Combination of Novartis drugs Tafinlar® and Mekinist® shows significant survival benefit in patients with metastatic melanoma
Media Release
May 20, 2015
Novartis investigational dual bronchodilator significantly improved lung function compared to single bronchodilators in patients with moderate-to-severe COPD in phase III studies
Media Release
Apr 24, 2015
Novartis Pharmaceuticals Corporation is first company to receive number one ranking two years in a row on DiversityInc Top 50 Companies for Diversity list
Media Release
Mar 30, 2015
Novartis announces FDA approval for Jadenu™ to simplify treatment administration for patients with chronic iron overload
Media Release
Mar 21, 2015
Novartis presents Cosentyx™ two-year efficacy and safety data showing sustainable effect in psoriasis patients
Media Release
Mar 20, 2015
New Novartis data show more Cosentyx™-treated psoriasis patients achieved clear or almost clear skin (PASI 90) compared to Stelara®
Media Release
Feb 13, 2015
Novartis' heart failure medicine LCZ696 granted FDA priority review
Media Release
Jan 21, 2015
Novartis announces FDA approval for first IL-17A antagonist Cosentyx™ (secukinumab) for moderate-to-severe plaque psoriasis patients

‹ Previous page
1
…
17
18
19
20
21
22
23
…
50
› Next page